United States (National)
Not enough data
Alan Murray's articles predominantly cover business and industry, with a significant focus on AI, CEOs, the economy, climate change, and the tech industry. His coverage attributes include citing data and expert commentary.
Given this information, Alan would likely be interested in receiving pitches related to trends or developments within these industries supported by credible data or insights from reputable experts. For example, pitches could include analyses of CEO strategies leveraging AI for business success or economic predictions incorporating climate metrics.
It's important to note that while government announcements are part of his coverage attributes, they form a smaller portion compared to citing data and expert commentary. Therefore, he may not be as focused on direct governmental news unless it significantly impacts the themes covered in his articles.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Biológicos Alexander, Berkeley Berkeley, Alan Murray, Peter Kedron, Antonio Medrano, Dipto Sarkar, Gordon Moore, Cullen Molitor, Alexandra D. Syphard, Rishi Singh, Janet Franklin
Amy E. Frazier Trisalyn Nelson Peter Kedron Somayeh Dodge Alan Murray Jelena Vukomanovic Janet Franklin
‘The Fuel for AI’ at FedEx
FedEx CEO Raj Subramaniam is my guest on this week's episode of WSJ Leadership Institute Presents: Leaders . And while Subramaniam may not be as
By: Alan Murray
Why This AI Data Center Building Company Dropped Traditional Job Titles
I had an interesting visit last week from Asher Genoot , the 31-year-old CEO of Hut 8 , which has transitioned from building bitcoin mining centers to building AI data centers—although it still runs both.
The Surprises That New CEOs Face
What Corporate Boards Aren’t Told
By: Alan Murray
Bill Gross’s AI Tool Could Supercharge the Number of Startups
The Biotech Leader Who Erased Team Lanes
Jeff Leiden has one of the best stories to tell in biotech. Leiden became CEO of struggling Vertex Pharmaceuticals in 2012, when the stock was under $40 a share.
